search
Back to results

Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes (RAISE)

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Rivoglitazone HCl
rivoglitazone HCl
rivoglitazone HCl
pioglitazone HCl
placebo
Sponsored by
Daiichi Sankyo Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring rivoglitazone HCl, pioglitazone HCl, thiazolidinedione, peroxisome proliferator-activated receptor gamma (PPAR gamma), type 2 diabetes mellitus

Eligibility Criteria

20 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • type 2 diabetes
  • HbA1c >6.5% and <10.0%
  • FPG >126 mg/dL (7 mmol/L) and < 270 mg/dL (15 mmol/L)

Exclusion Criteria:

  • History of type 1 diabetes
  • History of ketoacidosis
  • Current insulin therapy
  • C-peptide <0.5ng/mL
  • Imparied hepatic function
  • NYHA Class II-IV cardiac status or hospitalization for CHF or EF<40%
  • uncontrolled hypertension

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Placebo Comparator

Arm Label

1

2

3

4

5

Arm Description

0.5 mg rivoglitazone HCl tablets once daily for 12 weeks

1.0 mg rivoglitazone HCl tablets once daily for 12 weeks

1.5 mg rivoglitazone HCl tablets once daily for 12 weeks

30 mg pioglitazone HCl capsules once daily for 12 weeks

Matching rivoglitazone HCL placebo tablets and/or matching pioglitazone HCL placebo capsules

Outcomes

Primary Outcome Measures

Change in HbA1c from baseline for rivoglitazone HCl compared to that for placebo

Secondary Outcome Measures

Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to that for placebo. Change in HbA1c from baseline compared to that for pioglitazone HCl

Full Information

First Posted
December 14, 2007
Last Updated
February 6, 2009
Sponsor
Daiichi Sankyo Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT00575874
Brief Title
Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes
Acronym
RAISE
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Dose and Active Comparator-Controlled Dose-Response Study of Rivoglitazone (CS-011) in Patients With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
February 2009
Overall Recruitment Status
Completed
Study Start Date
August 2007 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
January 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Daiichi Sankyo Co., Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to assess the efficacy response of rivoglitazone HCl compared to pioglitazone HCl on the placebo-corrected change from baseline in HbA1c after 12 weeks of treatment in patients with type 2 diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
rivoglitazone HCl, pioglitazone HCl, thiazolidinedione, peroxisome proliferator-activated receptor gamma (PPAR gamma), type 2 diabetes mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Arm Title
2
Arm Type
Experimental
Arm Description
1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
Arm Title
3
Arm Type
Experimental
Arm Description
1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Arm Title
4
Arm Type
Active Comparator
Arm Description
30 mg pioglitazone HCl capsules once daily for 12 weeks
Arm Title
5
Arm Type
Placebo Comparator
Arm Description
Matching rivoglitazone HCL placebo tablets and/or matching pioglitazone HCL placebo capsules
Intervention Type
Drug
Intervention Name(s)
Rivoglitazone HCl
Intervention Description
0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
rivoglitazone HCl
Intervention Description
1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
rivoglitazone HCl
Intervention Description
1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
pioglitazone HCl
Intervention Description
30 mg capsules once daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
matching tablets or capsule once daily for 12 weeks
Primary Outcome Measure Information:
Title
Change in HbA1c from baseline for rivoglitazone HCl compared to that for placebo
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to that for placebo. Change in HbA1c from baseline compared to that for pioglitazone HCl
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: type 2 diabetes HbA1c >6.5% and <10.0% FPG >126 mg/dL (7 mmol/L) and < 270 mg/dL (15 mmol/L) Exclusion Criteria: History of type 1 diabetes History of ketoacidosis Current insulin therapy C-peptide <0.5ng/mL Imparied hepatic function NYHA Class II-IV cardiac status or hospitalization for CHF or EF<40% uncontrolled hypertension
Facility Information:
City
Hong Kong
Country
China

12. IPD Sharing Statement

Learn more about this trial

Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes

We'll reach out to this number within 24 hrs